QSAR and docking studies on xanthone derivatives for anticancer activity targeting DNA topoisomerase IIα

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 183-195

  Alam, Sarfaraz ^a   Khan, Feroz ^a  

^a CSIR CENTRAL INSTITUTE OF MEDICINAL AND AROMATIC PLANTS   (India)

Author keywords

ADMET; Drug likeness; HeLa cell line; Regression model

Indexed keywords

ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; ENZYME INHIBITOR; TUMOR ANTIGEN; XANTHONE DERIVATIVE;

ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DESIGN; MOLECULAR DOCKING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RISK ASSESSMENT; STATISTICAL MODEL; SYNTHESIS; TOXICITY;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DRUG DESIGN; ENZYME INHIBITORS; LINEAR MODELS; MOLECULAR DOCKING SIMULATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RISK ASSESSMENT; XANTHONES;

EID: 84893324658     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S51577     Document Type: Article

References (22)

1. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science. 1990;248(4953):358-361.
2. Blundell T, Sibanda BL, Pearl L. Three-dimensional structure, specificity and catalytic mechanism of renin. Nature. 1983;304(5923):273-275.
3. von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 1993; 363(6428):418-423.
4. Centers for Disease Control and Prevention. Cancer data and Statistics (webpage on the Internet). Available from http://www.cdc.gov/cancer/dcpc/data/. Accessed December 5, 2013.
5. Fortune JM, Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol. 2000;64:221-253.
6. Su QG, Liu Y, Cai YC, Sun YL, Wang B, Xian LJ. Anti-tumour effects of xanthone derivatives and the possible mechanisms of action. Invest New Drugs. 2011;29(6):1230-1240.
7. Yadav DK, Meena A, Srivastava A, Chanda D, Khan F, Chattopadhyay SK. Development of QSAR model for immunomodulatory activity of natural coumarinolignoids. Drug Des Devel Ther. 2010;4:173-186.
8. Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010;17(5):421-433.
9. Pouli N, Marakos P. Fused xanthone derivatives as antiproliferative agents. Anticancer Agents Med Chem. 2009;9(1):77-98.
10. Kuete V, Wabo HK, Eyong KO, et al. Anticancer activities of six selected natural compounds of some Cameroonian medicinal plants. PLoS One. 2011;6(8):e21762.
11. Koizumi Y, Tomoda H, Kumagai A, Zhou XP, Koyota S, Sugiyama T. Simaomicin α, a polycyclic xanthone, induces G1 arrest with suppression of retinoblastoma protein phosphorylation. Cancer Sci. 2009;100(2): 322-326.
12. Woo S, Kang DH, Nam JM, et al. Synthesis and pharmacological evaluation of new methyloxiranylmethoxyxanthone analogues. Eur J Med Chem. 2010;45(9):4221-4228.
13. Woo S, Jung J, Lee C, Kwon Y, Na Y. Synthesis of new xanthone analogues and their biological activity test - cytotoxicity, topoisomerase II inhibition, and DNA cross-linking study. Bioorg Med Chem Lett. 2007;17(5):1163-1166.
14. Cho HJ, Jung MJ, Woo S, et al. New benzoxanthone derivatives as topoisomerase inhibitors and DNA cross-linkers. Bioorg Med Chem. 2010;18(3):1010-1017.
15. Gao XM, Yu T, Cui MZ, et al. Identification and evaluation of apoptotic compounds from Garcinia oligantha. Bioorg Med Chem Lett. 2012;22(6):2350-2353.
16. Jun KY, Lee EY, Jung MJ, et al. Synthesis, biological evaluation, and molecular docking study of 3-(3′-heteroatom substituted-2′-hydroxy-1′-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitor. Eur J Med Chem. 2011;46(6):1964-1971.
17. Qidwai T, Yadav DK, Khan F, Dhawan S, Bhakuni RS. QSAR, docking and ADMET studies of artemisinin derivatives for antimalarial activity targeting plasmepsin II, a hemoglobin-degrading enzyme from P. falciparum. Curr Pharm Des. 2012;18(37):6133-6154.
18. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1-3):3-26.
19. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455-461.
20. Boda K, Seidel T, Gasteiger J. Structure and reaction based evaluation of synthetic accessibility. J Comput Aided Mol Des. 2007;21(6): 311-325.
21. Ee GC, Lim CK, Rahmat A, Lee HL. Cytotoxic activities of chemical constituents from Mesua daphnifolia. Trop Biomed. 2005;22(2): 99-102.
22. Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76(3):391-396.